TP53 and neoplasm: In agreement with this early phenotype, at the time of death, single and double p53 allele loss led to p53 dose-dependent decrease in survival (Fig. S1A), whereas tumor incidence is increased (Fig. S1B), and to a differential tumor spectrum (Fig. S1C), as described previously15,17–24.